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A B S T R A C T   
Objectives: To evaluate community-based health workers’ ability to identify cases of hypertension in pregnancy, 
safely deliver methyldopa and magnesium sulphate and make referrals when appropriate. 
Study design: This was part of Nigeria Community-Level Interventions for Pre-eclampsia (CLIP) cluster ran-
domized controlled trial (NCT01911494). Community-based Health Workers (CHW) recruited pregnant women 
from five Local Government Areas (clusters) and used mobile health aid for clinical assessment of pre-eclampsia. 
Main outcome measures: The primary outcome was the number of adverse events that occurred after the 
administration of magnesium sulphate and/or methyldopa to pregnant women by CHWs. 
Findings: Of 8790 women receiving mobile health-guided care, community-based health workers in Nigeria 
provided 309 women with hypertension (4.2% of delivered women), and safely administered 142 doses of 
intramuscular magnesium sulphate. Community Heath Extension Workers (CHEWs) and nurses gave fifty-two 
and sixty-seven doses of intramuscular magnesium sulphate respectively, twenty-three doses were given by 
other health care workers (midwives, community health officers, health assistants). The high rate of adminis-
tration by nurses can be explained by turf protection as well as their seniority within the health system. Also, 
CHEWs and nurses gave 124 doses of oral methyldopa and 126 urgent referrals were completed. There were no 
complications related to administration of treatment or referral. 
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Interpretation: These findings demonstrate the ability of community-based health workers to safely administer 
methyldopa and intramuscular magnesium sulphate. The use of task-sharing, therefore, could drastically reduce 
the three delays (triage, transport and treatment) associated with high maternal mortality and morbidity in rural 
communities in low- and middle-income countries.   
1. Introduction 
Nigeria has one of the highest maternal mortality ratios (MMR) in the 
world with an estimated 814 maternal deaths per 100 000 live births in 
2015 [1]. In the same year, India and Nigeria were responsible for over 
one third of all maternal deaths worldwide. Pregnancy hypertension is 
common and its incidence in south-western Nigeria was found to be as 
high as 10.2 [2]. Pre-eclampsia, and its complications, often occur in 
rural communities where there are inadequate resources available for 
emergency obstetric care [3–5]. The appropriate management of pre- 
eclampsia, which is typically available only in hospital settings, in-
volves supportive care with frequent maternal and foetal surveillance, 
anti-hypertensives, seizure prophylaxis, and timely delivery [6–11]. 
Magnesium sulphate (MgSO4) is the anticonvulsant of choice and is 
presently included in Nigeria’s essential medicines list as the first line 
drug in the management of pre-eclampsia and eclampsia [12,13]. Ten 
centres in Nigeria participated in the 1995 multicentre Collaborative 
Eclampsia Trial where magnesium was proven to be effective in the 
treatment of eclampsia, despite this, its use in the country remains 
limited [13,14]. Some barriers to the adoption of MgSO4 are poor 
dissemination of international guidelines, insufficient health worker 
training, the perceived need for intensive patient monitoring, stock outs 
and a lack of adequate manpower [14–16]. 
Many low- and middle-income countries (LMIC) utilize task-sharing 
to optimize the delivery of key effective maternal and newborn in-
terventions [17]. This involves delegating responsibilities previously 
reserved for highly trained health workers to existing or new cadres of 
health workers with either less or narrowly tailored training [18,19]. 
These health workers can be useful in bridging the gap between re-
cipients and providers and thus, reduce delays [17]. In Nigeria, 
community-based health workers are the first point of contact in the 
health system and provide a range of services in the home and at primary 
health centres (PHC). There is evidence to suggest that trained 
community-based health workers had good understanding of the fea-
tures of pre-eclampsia, could identify women at risk, and initiate care 
[20]. 
The Community Level Interventions for Pre-eclampsia (CLIP) study 
employed task-sharing to community-based health workers in Nigeria to 
identify and provide emergency treatment for pre-eclampsia prior to 
referral. This paper aims to assess the ability of community-based health 
workers to safely initiate lifesaving therapies (MgSO4 and methyldopa) 
for women with pre-eclampsia with the aid of an mHealth decision-aid, 
at primary health centres in Ogun State, Nigeria. 
2. Methods 
2.1. Study setting 
This study was conducted in Ogun State, Nigeria from March 01, 
2014 to January 31, 2016. Ogun State is populated mainly by the Yoruba 
ethnic group, roughly 50% of the population live in rural areas, and are 
served by a mix of public and private health care facilities. Of Ogun 
State’s twenty Local Government Areas (LGAs), ten were chosen for 
participation in the CLIP cluster randomized controlled trial 
(NCT01911494) [21]. Five of the ten LGAs were randomly chosen as 
intervention clusters (i.e. Remo North, Ogun Waterside, Odeda, Ijebu 
Northeast, and Yewa South), and within each cluster, five to seven wards 
were selected on the basis of ease of access into the community given the 
large size of the clusters. 
2.2. Clinical intervention 
The Community-based Health Workers (CHW), who implemented 
the CLIP study, were nurses, midwives, community health extension 
workers (CHEW), and health assistants (HAs), all of whom normally 
provide care at the community-level in Nigeria. The implementation 
itself involved clinical assessment of pregnant woman based on de-
mographics, symptoms and signs to identify likely cases of hypertensive 
disorders of pregnancy (HDP) and if the condition was severe, initiate 
treatment and referral. This process was guided by a mobile health 
application, PIERS on the Move (POM) [22]. The POM treatment algo-
rithm was based on the miniPIERS (Pre-eclampsia Integrated Estimate of 
RiSk) model that was predictive of adverse maternal outcome and 
perinatal death among women with HDPs in LMIC [22]. In brief, there 
were seven CLIP ‘triggers’ for action that resulted in recommendations 
to administer 750 mg oral methyldopa (for severe hypertension), 10 mg 
intramuscular MgSO4 (for presumed pre-eclampsia), and attend the 
nearest comprehensive emergency obstetric care (CEmOC) facility ur-
gently (for women with severe complications such as stroke) or 24 h (for 
non-severe hypertension). Successful use of this mobile application by 
minimally trained community-based health workers has previously been 
demonstrated [23]. 
A two-day training was provided for community-based health 
workers, at conveniently-located health centres, with refresher trainings 
provided every six months. Each community-based health worker was 
provided a transport allowance to encourage participation. Training 
facilitators were consultant obstetricians, medical officers, and nurses. 
Strategies used for training included didactic lectures, group work, case 
studies, role play, and practical demonstrations; importantly, pre- and 
post-tests were administered, and direct observations undertaken, to 
ensure that community-based health workers trained had adequate 
knowledge and skills. A ‘train-the-trainer’ model was used, where lead 
community-based health workers would train others in the facility who 
were not present on the initial day of training. In the training sessions, 
community-based health workers were provided information on: (i) the 
HDPs, focussing on the warning symptoms and signs of pre-eclampsia 
with the aid of pictograms; (ii) measurement of blood pressure at 
antenatal and postnatal visits using a low-cost, simple-to-use, semi- 
automated handheld blood pressure device validated for use in pre- 
eclampsia [24,25] (i.e., the Microlife 3AS1-2 and then the Microlife 
Vital Sign Alert (VSA) after January 23, 2015); (iii) dipstick measure-
ment of proteinuria, (iv) entry of basic demographic and pregnancy 
information into an electronic platform; (v) how to follow recommen-
dations provided by POM; (vi) administration of oral methyldopa and/ 
or intramuscular MgSO4, and (vi) counselling women about the need for 
referral [23]. 
This training supplemented health workers’ professional qualifica-
tions. Nurses had completed a three-year program at various nursing 
schools throughout Nigeria, and midwives completed an additional year 
and half maternity-focused training. CHEWs hold a Diploma in com-
munity health, having completed a three-year program, primarily at 
Schools of Health Technology. The CHEW curriculum is focused on 
community diagnosis and treatment of minor ailments and diseases in 
preparation for community outreach and assistance at PHCs, including 
monitoring of labour and delivery; only a few classes in the CHEW 
curriculum relate to the HDPs. The skills acquired include history taking, 
physical examination, vital sign monitoring, and administration of oral 
medications and intramuscular injections. Some nurses and CHEWs had 
also completed an additional one-year advanced course in primary 
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health to become community health officers (CHO) (n = 11). HAs are a 
lower cadre of community-based health workers whose skill set is more 
limited, consisting of taking vital signs, collecting preliminary clinical 
and pregnancy history. 
2.3. Study participants and data collection 
All women aged 15–49 years, who resided in the study area, and 
were identified as pregnant during routine antenatal care at a public 
PHC were eligible for participation in the CLIP trial. All eligible women 
who gave verbal and written consent were included in the study. 
Community-based health care workers used the POM application on a 
mobile android device to collect demographic information and record 
blood pressure, proteinuria, and other PIERS parameters data during 
routine antenatal clinics. 
2.4. Ethical approval 
Ethical approval for this study was obtained from the Health 
Research and Ethics Committee of Olabisi Onabanjo University Teach-
ing Hospital, Sagamu, Nigeria (as the in-country co-ordinating centre) 
and the Clinical Research Ethics Board of the University of British 
Columbia, Vancouver, Canada (as the central co-ordinating site) (H12- 
03497). All women and community-based health workers provided 
written informed consent for participation prior to enrolment. 
2.5. Outcomes 
This piece of process evaluation addressed the fidelity (how closely 
health workers followed the protocol and intervention as intended e.g. 
adherence to the recommended schedule of antenatal visits: 4-weekly 
during pregnancy until 28 weeks, fortnightly from 28 to 35 weeks and 
weekly thereafter, within 24 h of birth, and on approximately days 3, 7, 
and 14 after delivery), dose (how much of the clinical intervention was 
delivered), and reach (the number of recipients of the intervention) of 
the CLIP intervention [26]. 
2.6. Statistical analysis 
The aim of this analysis was to describe the ability of community- 
based health workers to administer life-saving emergency therapy in 
the study area from March 01, 2014 to January 31, 2016. Ability is 
assessed by the following proxies: acceptance rates and number of 
adverse events related to treatment. Means and standard deviations are 
presented for continuous variables. 
2.7. Role of the funding source 
The funder had no role in designing the study, data collection and 
analysis, the decision to publish, or the preparation of this manuscript. 
The corresponding author had full access to all the data in the study and 
final responsibility for the decision to submit for publication. 
3. Results 
In the 29 participating wards in five clusters, 170 (57.8%) 
community-based health workers were trained: 83 (48.8%) CHEWs, 14 
(8⋅2%) HAs, and 73 (42⋅9%) nurses. Twenty-five of the nurses had 
additional qualification as midwives. The most common reason why 
community-based health workers were not trained were personnel lo-
gistics at the health facility, unwillingness to take up additional re-
sponsibility, and turf protection among nurses and lower cadre health 
workers. 
These community-based health workers enrolled 8790 pregnant 
women (Table 1) during routine antenatal care at public PHCs. These 
women received an average of three visits per pregnancy, the majority of 
these visits were antepartum (78.7%); however, 27.5% of pregnancies 
received at least one postpartum visit. Few women (30.6%) received 
four or more antenatal visits, and even fewer received the newly rec-
ommended eight visits (4.7%). 
3.1. Community-level treatment of pre-eclampsia with MgSO4 and 
methyldopa 
The total number of study visits at PHCs with MgSO4 recommended 
was 154 (0⋅5% of total visits), 139 visits recommended methyldopa 
(0⋅4% of total visits), all whom also received MgSO4. The vast majority 
of these pregnancies were recommended treatment as a result of severe 
systolic hypertension (an average systolic blood pressure ≥ 160 mmHg): 
85⋅7% of visits with a recommendation for MgSO4 and 89⋅9% of visits 
with a recommendation for methyldopa (Table 2). All women who were 
provided treatment were also recommended referral within four hours 
to the nearest CEmOC facility. 
3.2. Acceptance of MgSO4 and methyldopa treatment 
Out of the 139 visits with methyldopa recommended, 124 (89⋅2%) 
accepted this treatment. Similarly, there was a high rate of acceptance 
for MgSO4, of the 154 MgSO4 recommendations, 136 (88⋅3%) accepted. 
Seventy-four percent (n = 127) of those recommended urgent referral, 
within four hours, accepted (Table 3). The most common reason for 
refusal of transport was permissions not obtained from husband or de-
cision-maker (n = 17.52% of refusal responses). In the study period, 67 
(49⋅3%) visits resulted in administration of MgSO4 by nurses, 52 
(38⋅2%) by CHEWs, 21 by midwives (15⋅4%), 1 (0⋅7%) by CHO and a HA 
provided MgSO4 on only one occasion (0⋅7%). 
Table 1 
Number of visits per pregnancy.   
Total 
pregnancies 
(N = 8790) 
mean (sd)/n 
(%) 
Total visits* 32 703 
Visits per pregnancy 3⋅7 
[± 2⋅8] 
Reach 
Total number of antenatal visits 
(% of all visits)  
25 745 
(78⋅7%) 
Pregnancies with at least one antenatal visit 




Antenatal visits per pregnancy  3⋅0 
[± 2⋅2] 
Pregnancies with ≥ 4 antenatal visits 
(% of total pregnancies with antenatal visits) 
2693 
(31⋅0%) 
Pregnancies with a visit every 4 weeks 
(% of total pregnancies with at least two visits and expected to 
have delivered by end of trial Jan 09, 2016) 
1721 
(24.5%) 
Total number of postpartum visits 
(% of total visits) 
6956 
(21⋅3%) 
Pregnancies with at least one postpartum visit 
(% of total pregnancies with at least two visits and expected to 
have delivered by end of trial Jan 09, 2016 (7016)) 
2416 
(34.4%) 
Postpartum visits per pregnancy 
(for all those with postpartum visits (2416)) 
2⋅9 
[± 1⋅2] 
Postpartum visits per pregnancy 
(for all those expected to be postpartum by the end of the trial) 
1⋅0 
[± 1⋅6] 
Pregnancies with ≥ 4 antenatal visits and at least one postpartum 
visit 
(for all those expected to be postpartum by the end of the trial) 
1043 
(14⋅9%)  
* All visits in this analysis include, at a minimum, completed blood pressure mea-
surements or emergency condition(s). 
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3.3. The safety of community-level administration of MgSO4, 
methyldopa, and referral 
There were no adverse events related to the administration of MgSO4 
or methyldopa in the study period. There was one injury in transport to a 
CEmOC facility, after thorough review of this case, it was confirmed that 
the woman suffered a minor injury to her arm due to seizures during 
transport in a poorly maintained vehicle; therefore, the injury was un-
likely related to the community management of pre-eclampsia. There 
were no cases of serious unexpected events related to any of the treat-
ments provided. In addition, there were no reported instances of 
mistreatment or overtreatment resulting in magnesium toxicity. There 
were also no reports of infection or hematoma at injection sites 
(Table 4). Sixty-five percent (n = 89) of pregnancies with MgSO4 
administered received a subsequent visit at some time during pregnancy 
or the first 42 days postpartum by a community-based health worker. 
Fifty-eight percent (n = 79) of women who received methyldopa had a 
subsequent visit at some point by a community-based health worker. 
4. Discussion 
In the CLIP Trial, community-based health workers were able to use 
the POM application to recognize women at risk of pre-eclampsia and 
eclampsia and to provide appropriate treatment and referral. 
There is considerable evidence regarding the treatment of pre- 
eclampsia and eclampsia by nurses, whereas the literature is far more 
limited regarding lay community-based health workers. There is a 
general consensus that it is within the scope of nurses and midwives to 
administer antihypertensives for severe hypertension in pregnancy; 
however, WHO did not recommend this task be performed by 
community-based health workers [17]. WHO has also recommended 
that nurses administer a loading dose of MgSO4 for prevention and 
treatment of eclampsia prior to referral [17]. It is important to note that 
this is recommended in the context of targeted monitoring and evalua-
tion. Studies carried out in Nigeria have demonstrated the ability of 
trained community-based health workers to triage and initiate pre- 
eclampsia treatment [27,28]. This has led to a change in national pol-
icy such that community-based health workers are authorized to 
administer a loading dose of MgSO4 before referral [28]. Although some 
studies have suggested that community-based health workers in LMIC 
could be employed to provide timely care to women with pre-eclampsia, 
there is currently no existing systematic review on the treatment of pre- 
eclampsia and eclampsia by community-based health workers [29]. A 
systematic review of tested dosing regimens of magnesium sulphate for 
managing pre-eclampsia and eclampsia demonstrated the necessity for 
further studies to determine if a MgSO4 loading dose could be safely 
administered in the community [30]. 
Pubmed was searched for relevant literature with the following key 
words: “community health workers”, “preeclampsia”, “eclampsia”, 
“magnesium sulphate”, “low- and middle-income countries”. 
To our knowledge, this is the first study in a LMIC to assess the ability 
of community-based health workers to initiate life saving therapies for 
pre-eclampsia with the assistance of an mHealth platform. Similar 
studies that examined the ability of CHEWs to provide MgSO4 in Nigeria 
did not include use of mHealth [27,28]. Moreover, the ability of the 
community-based health workers to safely administer antihypertensives 
Table 2 
MgSO4 and methyldopa treatment recommendations.   
Total visits with MgSO4 
recommended 
(N = 154) 
Total visits with a miniPIERS risk ≥ 25%* 5 
(3⋅2%) 




Total visits with severe systolic hypertension † 132 
(85⋅7%) 
Total visits with severe diastolic hypertension † 76 
(49⋅4%) 




Total visits with signs of recent seizure reported 9 
(5⋅8%) 
Total visits with signs of recent seizure confirmed 0 
(0%) 
Total visits with signs of recent stroke reported 0 
(0%) 
Total visits that reported ¥vaginal bleeding +
non-severe systolic hypertension 
0 
(0%)   
Total visits with methyldopa 
recommended 
(N ¼ 139) 
Severe systolic hypertension 125 
(89⋅9%) 
Total visits with severe diastolic hypertension† 71 
(50⋅1%) 




Triggers are not mutually exclusive. 
Severe systolic hypertension is defined as an average systolic blood pressure ≥160.†
Non-severe systolic hypertension is defined as average systolic blood pressure ≥140. 
Severe diastolic hypertension is defined as average diastolic blood pressure ≥110.†
After December 18th, 2015 MgSO4 was not recommended for any women known to 
be prior to 20 weeks gestation.  
¥ Antepartum bleeding of a spoonful or greater. 
* A miniPIERS score is determined by a predictive model for adverse outcome in 
pregnant/postpartum women with hypertension, a score of ≥25% indicates a likeli-
hood of adverse outcome of ≥25%. 
‡ Diastolic blood pressure was a trigger for treatment only after January 23, 2015. 
Table 3 
Acceptance of MgSO4 and methyldopa.  
Dose Total 
(N = 32 703) 
Accepted Refused Missing 



























Adverse events related to community treatment with MgSO4, methyldopa, and 
referral.   
Visits with MgSO4 administered 
(N = 136) 
Follow-up visits after treatment with MgSO4 89 
(65⋅4%) 
Visits with MgSO4 and an adverse event 0 
(0%) 
Visits with a hematoma 0 
(0%) 
Visits with an infection at injection site 0 
(0%)   
Visits with methyldopa 
administered 
(N ¼ 124) 
Follow-up visits after treatment with 
methyldopa 
79 
(58⋅1%)   
Visits with four-hour referral 
accepted 
(N ¼ 126) 
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was not assessed in previous studies. 
4.1. Implications of all the available evidence 
The findings from the CLIP study in Nigeria are far-reaching and 
could improve the health of pregnant women with pre-eclampsia. Task- 
sharing of emergency lifesaving treatments with the aid of mHealth may 
contribute to a significant reduction in maternal morbidity and 
mortality. 
In this study, women deemed to be at-risk were provided evidence- 
based treatment and referred by community-based health workers. 
There were no adverse events associated with this treatment. There was 
high level of acceptance among women who were recommended 
methyldopa (89⋅2%) for severe hypertension. The rate of acceptance for 
MgSO4 was similarly high (88⋅3%), despite the invasive nature of 
intramuscular treatment. These results suggest that community pro-
viders, if properly trained, can safely and appropriately administer 
MgSO4 and methyldopa to women with pre-eclampsia. These findings 
support previous studies that demonstrated the ability of minimally 
trained health workers to safely administer MgSO4 [27,28]. The ability 
of community-based health workers to safely initiate emergency treat-
ment at primary health centres could lead to a reduction of morbidity 
and mortality associated with the hypertensive disorders of pregnancy. 
In a study conducted in five PHCs in Kano State, community-based 
health workers were trained to detect severe pre-eclampsia/eclampsia, 
administer 10 mg of MgSO4 intramuscularly, treat any serious MgSO4- 
related reactions with calcium gluconate, and refer to facilities for 
ongoing management. Among women with severe pre-eclampsia/ 
eclampsia, more from study PHCs failed to attend facilities for 
ongoing care (90%) compared with those in control PHCs (56%) [26]. 
No adverse outcomes or toxicity was reported in association with PHC- 
administration of MgSO4 in the study [27]. In the CLIP study, 73.7% of 
the women accepted recommendation for referral which may suggest a 
higher acceptance of referral compared with the previous study con-
ducted in Kano State. This difference may be the consequence of 
extensive targeted training of health workers [19]. Additionally, health 
care providers resided in the communities in which they worked; this 
may have contributed to the higher level of adherence to recommen-
dations and a higher rate of follow-up post-treatment as they are trusted 
members of their communities. This high rate of follow-up indicates an 
ability to ensure safety and efficacy beyond immediate treatment at the 
community-level. 
This study illustrates the potential benefits to be gained through 
appropriate and careful task-sharing for maternal health interventions. 
Further evidence regarding effectiveness is required before the admin-
istration of MgSO4 and oral antihypertensives by lay health workers is 
included in international guidelines, such as WHO’s recommendations 
for optimizing health workers’ roles to improve access to key maternal 
and newborn health interventions [17]. 
Community-based health workers can serve as a bridge to the health 
facility in resource constrained settings. This study has shown that when 
properly trained, these providers can make appropriate decisions 
regarding treatment and referral of women with pre-eclampsia. Early 
detection, through regular high-quality antenatal care [31], and the 
provision of lifesaving therapies at the community-level may reduce 
maternal and perinatal morbidities and mortalities associated with pre- 
eclampsia. It is important to note that there may be cases of turf pro-
tection among the community-based health workers- some nurses and 
midwives may feel that CHEWs and other lower CHWs should not be 
empowered to ‘treat’ obstetric cases such as pre-eclampsia [19]. 
The CLIP trials in India, Pakistan and Mozambique were not a cost- 
effective approach to reducing adverse maternal and perinatal out-
comes as implemented; however, when women received at least eight 
home-based visits from community-based health workers, there was a 
cost-effective reduction in a composite of maternal and perinatal mor-
tality and morbidity, driven primarily by perinatal mortality [32]. 
4.2. Limitations of the study 
This study did not measure outcomes such as the reduction of 
maternal mortality. 
The CLIP intervention did not reduce adverse pregnancy outcomes in 
the CLIP trials in India, Pakistan and Mozambique (adjusted OR 1⋅17, 
95% CI 0⋅90–1⋅51; p = 0⋅24) [33–36]. The CLIP trial was initiated in 
Ogun State, Nigeria on 1 March 2015, and closed on 31 January 2016. 
Considerable logistical challenges in data-entry from paper forms to 
electronic database for the surveillance process led to the difficult de-
cision to halt the clinical research trial. The data gathered by the way of 
the mobile device was of high quality and integrity. This was done by 
mutual consent with the local research team and under the aegis of the 
local and institutional research and ethics board. 
Fetal outcomes were not available for women who received treat-
ment and/or referral as part of the CLIP trial, therefore, we cannot 
extrapolate the perinatal impact of these interventions. In addition, data 
regarding respiratory depression were not collected following treatment 
with MgSO4, nevertheless, existing evidence indicates this is not a grave 
concern with an occurrence of only 1.3% [37]. 
5. Conclusion 
These findings confirm the ability of community-based health 
workers to safely administer methyldopa and intramuscular magnesium 
sulphate. The use of task-sharing, therefore, could reduce the three de-
lays (triage, transport and treatment) associated with high maternal 
mortality and morbidity in rural communities in low- and middle- 
income countries. There is a need for further studies among 
community-based health workers in other similar settings. A systematic 
review of these studies may thus justify this as an international 
recommendation. 
Author contributions 
MV, AAA*, AAA and CN drafted the manuscript; LL, DT managed the 
data; LM, BP, AHS, HLN, SD, SS, ZB, OO, EJ, OS, DA, provided manu-
script review and input; OA, OAD, JS supervised and led study conduct; 
PvD conceptualized the study. 
Funding 
The University of British Columbia (PRE-EMPT), a grantee of the Bill 
& Melinda Gates Foundation . This work was supported, in whole or in 
part, by the Bill & Melinda Gates Foundation [OPP1017337]. Under the 
grant conditions of the Foundation, a Creative Commons Attribution 4.0 
Generic License has already been assigned to the Author Accepted 
Manuscript version that might arise from this submission. 
This work is part of the University of British Columbia PRE-EMPT 
(Pre-eclampsia/Eclampsia, Monitoring, Prevention and Treatment) 
initiative supported by the Bill & Melinda Gates Foundation. We would 
like to thank all members of the CLIP- NG team including: John Imaralu, 
Oluwole Ayodeji, Bisi Orengua, Bola Idowu-Ajiboye, Bimpe Osiberu, 
Busola Ibiezugbe, Abiodun Owoseje, and Kunle Adefabi and CLIP-CA 
team: Chirag Kariya, Tang Lee, Mansun Lui, Dustin Dunsmuir, Vivian 
Ukah, Asif Khowaja and Michelle La. 
We gratefully acknowledge the contribution of those involved in the 
study including the many participants and the communities of Ogun 
State. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
A.A. Adepoju et al.                                                                                                                                                                                                                             
Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health 25 (2021) 179–184
184
References 
[1] World Health Organization, UNICEF, United Nations, Department of Economic and 
Social Affairs, Population Division, World Bank. Trends in maternal mortality: 
1990 to 2015 : estimates by WHO, UNICEF, UNFPA, World Bank Group and the 
United Nations Population Division [Internet]. 2015 [cited 2020 May 22]. 
Available from: http://www.who.int/reproductivehealth/publications/monitorin 
g/maternal-mortality-2015/en/. 
[2] L.A. Magee, S. Sharma, H.L. Nathan, O.O. Adetoro, M.B. Bellad, S. Goudar, et al., 
The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and 
Nigeria: A prospective population-level analysis, PLoS Med. 16 (4) (2019), 
e1002783. 
[3] Adekanle DA, Akinbile TO. Eclampsia and pregnancy outcome at Lautech Teaching 
Hospital, Osogbo, SouthWest, Nigeria. Clin. Mother Child Health [Internet]. 2012 
[cited 2020 May 22];9(1). Available from: https://www.ajol.info/index.php/cmch 
/article/view/82026. 
[4] J. Wacker, M. Schulz, J. Frühauf, F.M. Chiwora, E. Solomayer, G. Bastert, Seasonal 
change in the incidence of preeclampsia in Zimbabwe, Acta Obstet. Gynecol. 
Scand. 77 (7) (1998) 712–716. 
[5] V.B. Bangal, P.A. Giri, A.S. Mahajan, Maternal and foetal outcome in pregnancy 
induced hypertension: A study from rural tertiary care teaching hospital in India, 
Int. J. Biomed. Res. 2 (12) (2011) 595–599. 
[6] Diagnosis and management of pre-eclampsia: an update [Internet]. [cited 2020 
May 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PM 
C2990902/. 
[7] P. von Dadelszen, L.A. Magee, Pre-eclampsia: an update, Curr. Hypertens. Rep. 16 
(8) (2014) 454. 
[8] C.M. Koopmans, D. Bijlenga, H. Groen, S.M. Vijgen, J.G. Aarnoudse, D.J. Bekedam, 
et al., Induction of labour versus expectant monitoring for gestational hypertension 
or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open- 
label randomised controlled trial, Lancet 374 (9694) (2009) 979–988. 
[9] P. Tajik, K. van der Tuuk, C.M. Koopmans, H. Groen, M.G. van Pampus, P.P. van 
der Berg, et al., Should cervical favourability play a role in the decision for labour 
induction in gestational hypertension or mild pre-eclampsia at term? An 
exploratory analysis of the HYPITAT trial, BJOG 119 (9) (2012) 1123–1130. 
[10] Management of gestational hypertension – the impact of HYPITATa | Semantic 
Scholar [Internet]. [cited 2020 May 22]. Available from: https://www.semanti 
cscholar.org/paper/Management-of-gestational-hypertension-%E2%80% 
93-the-impact-Pauli-Lauring/f9d606629b463b20235cc97a338c769f9146b7de. 
[11] P. Smith, J. Anthony, R. Johanson, Nifedipine in pregnancy, BJOG 107 (3) (2000) 
299–307. 
[12] D. Altman, G. Carroli, L. Duley, B. Farrell, J. Moodley, J. Neilson, et al., Do women 
with pre-eclampsia, and their babies, benefit from magnesium sulphate? The 
Magpie Trial: a randomised placebo-controlled trial, Lancet 359 (9321) (2002) 
1877–1890. 
[13] Which anticonvulsant for women with eclampsia? Evidence from the Collaborative 
Eclampsia Trial. Lancet. 1995;345(8963):1455–63. 
[14] C.M. Chama, A.D. Geidam, B. Bako, A.G. Mairiga, A. Atterwahmie, A shortened 
versus standard matched postpartum magnesium sulphate regimen in the 
treatment of eclampsia: a randomised controlled trial, Afr. J. Reprod. Health 17 (3) 
(2013) 131–136. 
[15] E. Okereke, B. Ahonsi, J. Tukur, S.M. Ishaku, A.B. Oginni, Benefits of using 
magnesium sulphate (MgSO₄) for eclampsia management and maternal mortality 
reduction: lessons from Kano State in Northern Nigeria, BMC Res Notes 8 (5) 
(2012) 421. 
[16] O. Oguntunde, Z. Charyeva, M. Cannon, W. Sambisa, N. Orobaton, I.A. Kabo, et al., 
Factors influencing the use of magnesium sulphate in pre-eclampsia/eclampsia 
management in health facilities in Northern Nigeria: a mixed methods study, BMC 
Pregnancy Childbirth 3 (15) (2015) 130. 
[17] WHO Recommendations: Optimizing Health Worker Roles to Improve Access to 
Key Maternal and Newborn Health Interventions Through Task Shifting [Internet]. 
Geneva: World Health Organization; 2012 [cited 2020 May 22]. (WHO Guidelines 
Approved by the Guidelines Review Committee). Available from: http://www.ncbi 
.nlm.nih.gov/books/NBK148518/. 
[18] B.D. Fulton, R.M. Scheffler, S.P. Sparkes, E.Y. Auh, M. Vujicic, A. Soucat, Health 
workforce skill mix and task shifting in low income countries: a review of recent 
evidence, Human Resour. Health 9 (1) (2011) 1. 
[19] D.O. Akeju, M. Vidler, J.O. Sotunsa, M.O. Osiberu, E.O. Orenuga, O.T. Oladapo, et 
al., Human resource constraints and the prospect of task-sharing among 
community health workers for the detection of early signs of pre-eclampsia in Ogun 
State, Nigeria, Reprod. Health 13 (Suppl 2) (2016) 111. 
[20] Community health workers’ knowledge and practice in relation to pre-eclampsia in 
Ogun State, Nigeria: an essential bridge to maternal survival | Reproductive Health 
| Full Text [Internet]. [cited 2020 May 22]. Available from: https://reproductive-h 
ealth-journal.biomedcentral.com/articles/10.1186/s12978-016-0218-9. 
[21] Protocol 13PRT/9313 [Internet]. [cited 2020 Jun 16]. Available from: http 
s://www.thelancet.com/protocol-reviews/13PRT-9313. 
[22] B.A. Payne, J.A. Hutcheon, J.M. Ansermino, D.R. Hall, Z.A. Bhutta, S.Z. Bhutta, et 
al., A risk prediction model for the assessment and triage of women with 
hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre- 
eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study, 
PLoS Med. 11 (1) (2014), e1001589. 
[23] J. Lim, G. Cloete, D.T. Dunsmuir, B.A. Payne, C. Scheffer, P. von Dadelszen, et al., 
Usability and feasibility of PIERS on the move: an mhealth app for pre-eclampsia 
triage, JMIR Mhealth Uhealth 3 (2) (2015), e37. 
[24] H.L. Nathan, A. de Greeff, N.L. Hezelgrave, L.C. Chappell, A.H. Shennan, Accuracy 
validation of the Microlife 3AS1-2 blood pressure device in a pregnant population 
with low blood pressure, Blood Pressure Monit. 20 (5) (2015) 299–302. 
[25] A. de Greeff, H. Nathan, N. Stafford, B. Liu, A.H. Shennan, Development of an 
accurate oscillometric blood pressure device for low resource settings, Blood Press 
Monit. 13 (6) (2008) 342–348. 
[26] S. Sharma, O.O. Adetoro, M. Vidler, S. Drebit, B.A. Payne, D.O. Akeju, et al., 
A process evaluation plan for assessing a complex community-based maternal 
health intervention in Ogun State, Nigeria, BMC Health Serv. Res. 17 (1) (2017) 
238. 
[27] S. Ishaku, B. Ahonsi, J. Tukur, O. Ayodeji, Attrition from care after the critical 
phase of severe pre-eclampsia and eclampsia: Insights from an intervention with 
magnesium sulphate in a primary care setting in northern Nigeria, Health 5 (9) 
(2013) 720–726. 
[28] Scale-up of magnesium sulfate for treatment of pre-eclampsia and eclampsia in 
Nigeria - Danmusa - 2016 - International Journal of Gynecology & Obstetrics - 
Wiley Online Library [Internet]. [cited 2020 May 22]. Available from: http 
s://obgyn.onlinelibrary.wiley.com/doi/full/10.1016/j.ijgo.2016.06.001. 
[29] T. Firoz, H. Sanghvi, M. Merialdi, P. von Dadelszen, Pre-eclampsia in low and 
middle income countries, Best Pract. Res. Clin. Obstet. Gynaecol. 25 (4) (2011) 
537–548. 
[30] R. Gordon, L.A. Magee, B. Payne, T. Firoz, D. Sawchuck, D. Tu, et al., Magnesium 
sulphate for the management of preeclampsia and eclampsia in low and middle 
income countries: a systematic review of tested dosing regimens, J. Obstet. 
Gynaecol. Can. 36 (2) (2014) 154–163. 
[31] E. Sevene, S. Sharma, K. Munguambe, C. Sacoor, A. Vala, S. Macuacua, et al. 
Community-Level interventions for Pre-eclampsia (CLIP) in Mozambique: a cluster 
randomised controlled trial. Pregnancy Hypertens. [Internet]. 2020 May 14 [cited 
2020 May 22]; Available from: http://www.sciencedirect.com/science/article/pii/ 
S2210778920300684. 
[32] J.N. Bone, A. Khowaja, M. Vidler, B.A. Payne, M.B. Bellad, S.S. Goudar, A. 
Mallapur, K. Munguambe, R. Qureshi, C. Sacoor, E. Sevene, G. Frederix, Z. Bhutta, 
C. Mitton, L.A. Magee, P. von Dadelszen, Economic analysis of the CLIP Trials in 
India, Pakistan and Mozambique. Implement. Sci. In press. 
[33] P. von Dadelszen, Z.A. Bhutta, S. Sharma, J. Bone, J. Singer, H. Wong, et al., The 
Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials 
in Mozambique, Pakistan, and India: an individual participant-level meta-analysis, 
Lancet 396 (10250) (2020) 553–563. 
[34] M.B. Bellad, S.S. Goudar, A.A. Mallapur, S. Sharma, J. Bone, U.S. Charantimath, et 
al., Community level interventions for pre-eclampsia (CLIP) in India: A cluster 
randomised controlled trial, Pregnancy Hypertens. 21 (2020) 166–175. 
[35] E. Sevene, S. Sharma, K. Munguambe, C. Sacoor, A. Vala, S. Macuacua, et al., 
Community-level interventions for pre-eclampsia (CLIP) in Mozambique: A cluster 
randomised controlled trial, Pregnancy Hypertens. 21 (2020 Jul) 96–105. 
[36] R.N. Qureshi, S. Sheikh, Z. Hoodbhoy, S. Sharma, M. Vidler, B.A. Payne, et al., 
Community-level interventions for pre-eclampsia (CLIP) in Pakistan: A cluster 
randomised controlled trial, Pregnancy Hypertens. 28 (22) (2020) 109–118. 
[37] J.M. Smith, R.F. Lowe, J. Fullerton, S.M. Currie, L. Harris, E. Felker-Kantor, An 
integrative review of the side effects related to the use of magnesium sulfate for 
pre-eclampsia and eclampsia management, BMC Pregnancy Childbirth 5 (13) 
(2013) 34. 
A.A. Adepoju et al.                                                                                                                                                                                                                             
